Drug Profile
RA 123456
Alternative Names: Ca/calmodulin kinase II; CaMKII modulatorLatest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Developer Sanofi; University Hospital Regensburg
- Class
- Mechanism of Action Calmodulin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atrial fibrillation; Heart failure
Most Recent Events
- 26 Sep 2023 Discontinued - Preclinical for Atrial fibrillation in USA, Germany (PO)
- 26 Sep 2023 Discontinued - Preclinical for Heart failure in USA, Germany (PO)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Atrial-fibrillation in Germany (PO)